Cubist Pharmaceuticals is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

Product Pipeline


Gram-negative CXA-201

for cUTI (complicated urinary tract infection) and
cIAI (complicated intra-abdominal infection)

The FDA has accepted with Priority Review Cubist’s New Drug Application for investigational antibiotic ceftolozane/tazobactam, for which the Company is seeking FDA approval for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections…


News & Press

20 Jun

Cubist’s SIVEXTRO™ (tedizolid phosphate) Approved in U.S. to Treat Serious Skin Infections—Including Those Caused by MRSA

SIVEXTRO offers a short six-day course of therapy to physicians in once daily I.V. and oral treatment options

Careers at Cubist


Meet Alice

Vice President of Medical Affairs, International

Alice was hired in the fall of 2013 as Vice President of Medical Affairs, International, charged with building Cubist’s Medical…

Upcoming Events

There are no events available at this time. Please check back soon.

Investor Center

Cubist Pharmaceuticals Loading…